Please login to the form below

Not currently logged in
Email:
Password:

Vimpat

This page shows the latest Vimpat news and features for those working in and with pharma, biotech and healthcare.

Tecentriq’s triple negative breast cancer use among key CHMP nods

Tecentriq’s triple negative breast cancer use among key CHMP nods

UCB’s Vimpat (lacosamide) also gained a thumbs up in the epilepsy market, with a recommendation in partial-onset seizures with or without secondary generalisation. ... This most recent indication sees Vimpat continue on its trajectory to blockbuster

Latest news

  • UCB looks to pipeline with five years left for twin blockbusters UCB looks to pipeline with five years left for twin blockbusters

    CEO outlines pipeline promise, won't write off post-Brexit UK. Mid-sized pharma company UCB has seen its epilepsy treatment Vimpat break through the $1bn+ annual revenues mark, joining its ... Vimpat is forecast to reach 1.4bn by 2022, the year its US

  • UCB bags FDA approval for epilepsy drug Briviact UCB bags FDA approval for epilepsy drug Briviact

    Belgium-headquartered UCB is already an established player in epilepsy with drugs such as Vimpat (lacosamide) and Keppra (levetiracetam), which is off-patent in most major markets. ... Vimpat added another 495m.

  • UCB wins European approval for epilepsy drug Briviact UCB wins European approval for epilepsy drug Briviact

    The drug adds to an epilepsy treatment portfolio at UCB currently represented by Vimpat (lacosamide) - with sales of 495m in the first nine months of 2015 - along with Keppra (levetiracetam) which

  • UCB boosted by core medicines growth UCB boosted by core medicines growth

    Revenue was boosted by its core product range, with Crohn's disease and psoriatic arthritis treatment Cimzia (certolizumab pegol); epilepsy medicine Vimpat (lacosamide) and Parkinson's disease and restless leg syndrome ... Sales of Vimpat increased by 15%

  • UCB submits brivaracetam for use in epilepsy UCB submits brivaracetam for use in epilepsy

    The company has since turned to other drugs in its epilepsy portfolio, including Vimpat (lacosamide). ... At the end of last year UCB announced a partnership with Daiichi Sankyo to bring Vimpat to Japan.

More from news
Approximately 7 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2013 Pharma deals during November 2013

    Certainly the good performances from key products such as Cimzia, Vimpat and Neupro may well appeal to those companies feeling a little pipeline bereft.

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    For UCB, this notion is especially important considering its focus on severe diseases, including the recent launches of Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease; Vimpat (lacosamide) for ... As for the future of the company,

  • Interview with Roch Doliveux, UCB Interview with Roch Doliveux, UCB

    It is the same with Vimpat. Peak sales were once 350m; now, estimates are at least 1.2bn. ... Vimpat treats a subset of epilepsy, partial onset seizures. One in three patients has this refractory type of seizure.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...

Infographics